glatiramer

glatiramer

 [glah-tir´ah-mer]
an immunomodulator used as the acetate ester to reduce relapses in multiple sclerosis; administered by subcutaneous injection.

glatiramer

A mixture of synthetic polypeptides that act on the immune system and are claimed to reduce substantially the frequency of relapses in people with relapsing MULTIPLE SCLEROSIS. Its use is restricted to those who have suffered a relapse in the previous two years. The drug is unsuitable for patients who are severely affected and unable to get about unaided. A brand name is Copaxone.
References in periodicals archive ?
Indirect analysis suggests Ocrevus can cut the number of relapses compared to interferon beta-1b, glatiramer acetate, dimethyl fumarate, fingolimod, and teriflunomide and is as effective as alemtuzumab and natalizumab.
"We feel that it is important for the FDA to have access to Peptimmune's data resulting from our characterization of Copaxone using proprietary methods when considering ANDAs (Abbreviated New Drug Applications) for generic forms of glatiramer acetate.
New data analyzed from ongoing or completed clinical trials of drugs were presented, including promising results from a phase 2 study of daclizumab (PDL Biopharma and Biogen Idec) in people with relapsing MS who were taking interferons; preliminary results from two studies of low-dose naltrexone; and evidence that Copaxone (glatiramer acetate, Teva Pharmaceutical Industries Ltd.) reduced the risk of MS and delayed its development in individuals with CIS, clinically isolated syndrome, a first event suggestive of MS.
Glatiramer acetate (Copaxone) was thought to work by gumming up T cells and other fighters' weapons, but recent research suggests that some of its benefits derive from its ability to call up another unit in the immune system--special forces trained to block the immune cells that are attacking.
Abstract: This study examined the experiences of a group of patients with relapsing multiple sclerosis who received glatiramer acetate for the treatment of their illness.
Issuing its long-awaited final guidance today, the National Institute for Clinical Excellence (Nice) said "on the balance of its clinical and cost effectiveness", neither beta interferon nor another MS drug - glatiramer acetate - is recommended for NHS treatment in England and Wales.
The organisation said that "on the balance of their clinical and cost effectiveness" neither beta interferon nor another MS drug, glatiramer acetate, should be recommended for NHS treatment in England and Wales.
Additional data further contribute to the scientific understanding of the efficacy, safety and tolerability of Teva's COPAXONE for the treatment of relapsing multiple sclerosis, including up to seven-year results from the Glatiramer Acetate Low-Frequency Administration study and an abstract assessing pregnancy outcomes in RMS patients exposed to COPAXONE 20 mg/mL during all three trimesters.
- Holzkirchen, Germany-based biosimilar medicines specialist Sandoz, a Novartis division, has launched Glatopa (glatiramer acetate injection) 40 mg/mL following receipt of US FDA approval, the company said.
The company has received approval for Glatopa 40mg/mL as a fully-substitutable, AP-rated generic version of Teva Pharmaceutical Industries' three times-a-week Copaxone 40mg/mL therapy (glatiramer acetate injection).
(See page 22 of this issue for the story on William Sibley.) As early as the 1970's we were funding research on glatiramer acetate, originally called co-polymer 1, now known as Copaxone.